InnoPharma

What InnoPharma does

InnoPharma is a private specialty pharmaceutical company founded in 2005 and headquartered in Piscataway, New Jersey, that develops niche-generic, specialty pharmaceutical, and bio-pharmaceutical products. The company targets therapeutic categories where formulation complexity, limited commercial demand, or specialty distribution requirements create barriers that discourage larger generic manufacturers, allowing InnoPharma to compete on focused execution rather than scale. Its product scope spans both small-molecule niche generics and bio-pharmaceuticals, indicating an intent to move up the value chain from commodity generics into higher-margin specialty and biologic-adjacent products.

Operationally, InnoPharma is a small organization of 51-100 employees, consistent with a development-to-commercial-stage specialty pharma that relies on outsourced or partnered manufacturing and a concentrated U.S. distribution footprint. The company's business model is product sales through standard pharmaceutical wholesale, specialty distribution, and institutional channels, with revenue mechanics typical of branded-generic and specialty pharma (per-unit margin on dispensed prescriptions, supplemented by 340B/contracting economics, though no pricing model is publicly disclosed). The company has not raised public capital or listed equity; all disclosed capital events are private financing rounds totaling approximately $43 million across 2011-2013 from healthcare-specialist investors including Thomas, McNerney & Partners, NXT Capital, Comerica, and Athyrium Capital Management.

Important data-quality caveat: the aggregated source material includes extensive content describing Pfizer Inc. (founded 1849, NYSE: PFE, ~$1.5B+ market cap, 175+ year operating history, global biopharmaceutical operations) that does not correspond to the firmographic record of InnoPharma (founded 2005, 51-100 employees, private, Piscataway NJ). That Pfizer-attributed content (covering PfizerPro, PfizerForAll, RxPathways, IBRANCE approvals, and 2026 dividend declarations) has been excluded from the analytical conclusions above because it describes a different company. The analysis is therefore grounded in the firmographic, financing, and pipeline-scope data clearly attributable to InnoPharma.

Name

InnoPharma

Legal name

Pfizer Inc.

Website

https://innopharmainc.com

Company type

Public

Founded year

1849

Operating status

Operating

Headcount range

51–100 employees

Short description

InnoPharma is a private specialty pharmaceutical company founded in 2005 in Piscataway, New Jersey, that develops niche-generic, specialty, and bio-pharmaceutical products, with 51-100 employees and approximately $43M raised since 2011.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Niche generic drugs
• Specialty pharmaceuticals
• Bio-pharmaceutical products
• Generic drug development
• Pharmaceutical formulations

Headquarters

HQ city

Piscataway

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from branded pharmaceutical products across multiple therapeutic areas including Internal Medicine, Inflammation & Immunology, Vaccines, and Oncology. Products are distributed globally through direct channels and distributor networks.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

InnoPharma develops niche-generic, specialty pharmaceutical, and bio-pharmaceutical products. The company focuses on difficult-to-formulate generic formulations and specialty pharmaceutical products targeting the U.S. healthcare market, operating from its headquarters in Piscataway, New Jersey.

Product overview

Pfizer is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and vaccines. The company operates across four primary therapeutic areas: Internal Medicine (obesity, type 2 diabetes, cardiovascular and kidney diseases), Inflammation & Immunology, Vaccines, and Oncology. Pfizer offers its products through patient assistance programs like Pfizer RxPathways, and maintains a product pipeline with candidates across Phase 1, Phase 2, Phase 3, and Registration stages.

Differentiator

Problem solved

Functional benefit

Brands

• PfizerForAll: Patient-facing platform for prescription management and health information.
• PfizerPro
• Pfizer RxPathways
• Pfizer CentreOne

Quantifiable outcome

• FDA approved IBRANCE regimen for HR+, HER2+ metastatic breast cancer frontline maintenance

Segments3 records

Ideal customer profiles1 record

API detail

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core and minor.

• Pfizer CentreOnecoreStrategic or Co-development PartnerPfizer CentreOne is a strategic partner program under the Pfizer Partners umbrella, providing manufacturing and development services as part of Pfizer's ecosystem of strategic collaborations.
• Patient Advocacy & Engagement PartnerscoreStrategic or Co-development PartnerPfizer partners with patient advocacy organizations to ensure patient voices are incorporated into drug development and healthcare delivery, supporting patient-centered innovation.
• Healthcare Professional OrganizationscoreStrategic or Co-development PartnerPfizer works with healthcare professionals and organizations on research collaborations, clinical trials, and professional education to advance medical knowledge and patient care.
• Research and Business Development PartnerscoreStrategic or Co-development PartnerPfizer engages in research and business development partnerships to advance pharmaceutical innovation, co-develop therapies, and expand pipeline capabilities across therapeutic areas.
• Grant RecipientsminorOthersPfizer provides grants to support global health initiatives, research, and healthcare programs through its funding programs for grant seekers.
• Supplier & Business-to-Business PartnersminorOthersPfizer maintains relationships with suppliers and B2B partners for manufacturing, raw materials, and operational support across its global supply chain.

Scale indicators3 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Lannett Company: US-based specialty and generic pharmaceutical manufacturer with a similar mid-size footprint, focused on niche generics and specialty dosage forms — directly comparable in business model, customer base, and molecule selection strategy to InnoPharma.
• Upsher-Smith Laboratories: Private US specialty and generic pharmaceutical company developing, manufacturing, and marketing niche prescription products — closely aligned with InnoPharma's niche-generic specialty positioning and private mid-market profile.
• Amneal Pharmaceuticals: US-based developer and manufacturer of generic and specialty pharmaceuticals across a broad niche-generic and specialty portfolio — comparable to InnoPharma in molecule selection philosophy and therapeutic breadth within specialty.
• Alvogen: Privately held specialty and generic pharmaceutical company focused on niche, complex generics and specialty brands — directly comparable to InnoPharma on the niche-generic/specialty mix and on operating as a privately held mid-market player.
• Apotex: Large privately held Canadian generic and specialty pharmaceutical manufacturer with significant US niche-generic presence — overlaps with InnoPharma's private status and emphasis on differentiated generic and specialty molecules.

Broad incumbents

• Endo International: Larger specialty and generics pharmaceutical company operating across branded specialty, sterile injectables, and generics — broader portfolio but overlapping with InnoPharma in specialty/generic molecule strategy.
• Mallinckrodt: Established specialty pharmaceutical company focused on branded specialty, generics, and hospital/sterile injectables — comparable to InnoPharma's specialty and bio-pharma positioning but at materially greater scale.
• Hikma Pharmaceuticals: Global specialty and generic pharmaceutical company with a substantial US generics and injectables business — broader reach than InnoPharma but overlapping on specialty generics and complex dosage forms.
• Glenmark Pharmaceuticals: India-headquartered specialty and generics pharmaceutical company with US niche-generic and specialty footprint — comparable to InnoPharma in molecule-niche strategy while operating at significantly larger scale.
• Bausch Health (formerly Valeant): Diversified specialty pharmaceutical company with branded specialty, generics, and OTC businesses — adjacent to InnoPharma's niche-generic specialty positioning though operating across a much wider portfolio.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xtwitter.com/Pfizer
• YouTubeyoutube.com/Pfizer
• Facebookfacebook.com/Pfizer
• LinkedInlinkedin.com/company/pfizer
• Instagraminstagram.com/pfizerinc

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InnoPharma